Read More

Enveric Biosciences nabs patent for “next-gen” psilocin prodrug

Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its drug candidate EB-002, the company announced Wednesday. The patent (No. 11,945,778) covers methods of treatment for a range of brain neurological disorders, including sleep disorders, depression, substance-related disorders, and headaches, the company said. Those conditions involve similar neurotransmitter systems. …

MarTech Interview with Eli Finkelshteyn, Founder and CEO at Constructor

Tweet!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’); Eli Finkelshteyn, Founder and CEO at Constructor, shares more on Constructor’s recent funding and the latest in GenAI developments in this chat with MarTechSeries: _______ Hi Eli — tell us about yourself and more about what inspired Constructor. Happy to, and thanks for having …